1.0Public Citizenhttps://www.citizen.orgDiane Krauthamerhttps://www.citizen.org/author/dkrauthamer/Testimony Before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Celecoxib - Public Citizenrich600338<blockquote class="wp-embedded-content" data-secret="ufwg5aHuBY"><a href="https://www.citizen.org/article/testimony-before-the-fdas-arthritis-advisory-committee-and-drug-safety-and-risk-management-advisory-committee-regarding-celecoxib/">Testimony Before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Celecoxib</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/testimony-before-the-fdas-arthritis-advisory-committee-and-drug-safety-and-risk-management-advisory-committee-regarding-celecoxib/embed/#?secret=ufwg5aHuBY" width="600" height="338" title="“Testimony Before the FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding Celecoxib” — Public Citizen" data-secret="ufwg5aHuBY" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]> */
</script>
In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen argued that because of the major limitations of the PRECISION trial, no meaningful conclusions can be drawn from the trial regarding the cardiovascular safety of celecoxib relative to ibuprofen and naproxen.https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg1200628